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Abstract – Cervical cancer is one of the leading causal cancer-related fatalities in the world. Cervical 
cancer patients can be treated by conventional treatment such as surgery, radiotherapy, chemotherapy, 
medications and combination treatments. Currently, more targeted treatments are being developed to 
cure cervical cancer. The treatments include immunotherapy, virotherapy and gene therapy which will 
be discussed in this paper. In immunotherapy, the synergy of CTLA-4 suppression and PD-1/PDL-1 
immune checkpoint inhibition targeting their corresponding pathways enhanced the human immune 
system resulting a promising treatment effects. Oncolytic viruses such as Newcastle disease virus 
selectively infect and kill cancerous cells/tissues without harming normal cells/tissues. This character 
has made them a potential modality in combating cancer which popularly known as oncolytic 
virotherapy. Gene therapy delivers modified genetic materials to the target cancer cells via viral and 
non-viral vectors. It is used to target the abnormal gene, to increase cells’ susceptibility towards drugs 
or conventional therapy, to induce tumour cells apoptosis, to enhance tumour cell immunogenicity 
recognition and to inhibit the oncogene expression. The objective of this minireview is to add to the 
general knowledge on aforementioned therapeutic strategies against cervical cancer. 
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Introduction 
Cervical cancer is a cancer that developed in woman’s cervix and one of the leading causal cancer-
related fatalities in the world. Cervical cancer is asymptomatic during early stage, otherwise it can be 
treated via surgery or radiation upon detection. Infection by human papillomavirus (HPV) strains HPV-
16 and HPV-18, also known as the high-risk HPVs, is the most common cause of cervical cancer. Any 
activities which lead to the exposure of HPV infection such as having multiple sexual partners and 
engaging in sexual contact at early age in life may also cause the disease (National Health Science, 
2018). Other possible reasons of cervical cancer include aberrant activation of hepatocyte growth 
factor/c-mesenchyal-epithelial transition (HGF/c-Met) signalling pathway (Boromand et al., 2017) and 
overexpression of microRNA-9 (miR-9) (Zhang et al., 2018). Most cervical cancer cases are 
preventable by routine screening and vaccination, nonetheless, metastatic cervical cancer often results 
in poor prognosis (Yung et al., 2013). Screening of the cancer for early detection can be done via PAP 
smear test where the general practitioner would swab a small sample of cells from the cervix area and 
observed for any abnormalities under microscopes (National Health Service, 2018). Cervical cancer 
may be treated via surgery, radiotherapy, chemotherapy, medications and other targeted treatments 
including combination therapy (American Cancer Society, 2018; National Health Service, 2018). This 
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minireview will be focusing on three therapeutic strategies, namely immunotherapy, oncolytic 
virotherapy and gene therapy. The exploration of these strategies may add to the general knowledge on 
aforementioned therapeutic strategies against cervical cancer even to those who are not in the field of 
medicine. 
 
Immunotherapy 
Cancer immunotherapy is defined as the utilization of naturally derived or synthetically generated 
components to stimulate or enhance body immune response to fight against cancer. Immunotherapy is 
able to restore the damped anti-cancer immune response (Drake et al., 2014). The general concept of 
immunotherapy is to achieve a response against tumour by stimulating immune defences, which are 
mostly impaired among cancer patients (Disis, 2014; Mandal and Chan, 2016).  
 
The roles of immune checkpoints in regulating immunity 
The key requirement of immune system is crucial for self-tolerance, to prevent the immune cells from 
attacking cells indiscriminately. To prevent autoimmunity, activation of immune checkpoints pathway 
is vital to regulate activation of T cells at multilevel steps during an immune response (Fife and 
Bluestone, 2008; Goldrath and Bevan, 1999). Immune checkpoints are referred as the plethora of 
inhibitory pathways of the immune system for the maintenance of self-tolerance and immune 
homeostasis (Pardoll, 2012).  
 
Under normal conditions, a balance between T cell activation and the inhibitory pathways are used to 
prevent autoimmunity or immune deficiency. Pardoll (2012) described that the expression of immune 
checkpoint proteins could be dysregulated by tumours as an important immunity resistance mechanism. 
In context of cancer condition, overexpression of inhibitory T cell receptors on their own cell surface 
permits inhibition of anti-tumour immune response. In most cancer immunotherapies, cytotoxic T-
lymphocyte antigen 4 (CTLA-4) and programmed death receptor-1 (PD-1) are the main inhibitory 
receptors that being expressed on T cells (Chen and Flies, 2013; Pardoll, 2012), also referred as immune 
checkpoints that belong to immunoglobulin superfamily (Brunet et al., 1987; Ishida et al., 1992).  
 
CTLA-4 immune checkpoint expressed on the surface of T cells interacts with ligand cluster of 
differentiation 80 (CD80) and for PD-1, it interacts with its programmed death ligand-1 (PDL-1) on 
antigen presenting cells (APCs). According to Fife et al. (2009), CTLA-4 drives the immune checkpoint 
inhibitors, as it halts potentially autoreactive T cells at the initial stage of naïve T cell activation. In 
contrast, PD-1 pathway which primarily occurs in peripheral tissues, will regulate the previously 
activated T cells at the later stages of immune response. Expression of PD-1 also being presented on B 
cells, dendritic cells (DCs), monocytes and natural killer (NK) T-cells upon activation (Brunet et al., 
1987; Riley, 2007).  
 
Functions of PD-1 and its ligand, PDL-1, in cervical cancer 
High expression of PDL-1 is commonly observed on cell surface of solid tumours. This expression has 
a large proportion on tumour infiltrating lymphocytes (TILs) (Ahmadzadeh et al., 2009). It has been 
reported that expressions of PDL-1 are 95% of cervical intraepithelial neoplasia and 80% of squamous 
cell carcinomas (Mezache et al., 2015). Within tumour microenvironment, PDL-1 is expressed for 
oncogenic signalling or induced to inflammatory cytokines (Jenkins et al., 2018). The complexity of 
PDL-1 neither guarantees nor precludes response to PD-1/PDL-1 blockade. However, murine studies 
had confirmed the contribution of PDL-1 on both tumour cells and immune cells are vital to determine 
response to PD-1 blockade (Figure 1(A)) (Juneja et al., 2017, Lau et al., 2017). 
 
Discovery of PD-1 and PDL-1 pathways emerges as a result of the necessity to control the degree of 
inflammation at the site of antigen expression. The cytokines produced by T cells will modulate PDL-
1 expression in tissues hence activate the PD-1 proteins (Mahoney et al., 2015). This condition will lead 
to immune tolerance, where the immune system loses the control to mount an inflammatory response.  
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Figure 1: (A) Immune checkpoint, programmed death receptor-1 (PD-1) expressed on T cell surface 
binds to its programmed death ligand-1 (PDL-1) on tumour cell. (B) Nivolumab inhibits the 
interaction of PD-1 to its ligand PDL-1 (e.g. Lau et al., 2017; Topalian et al., 2014).  
 
PD-1/PDL-1 immune checkpoint inhibition 
Pharmacologically, the inhibitors of PD-1/PDL-1 prevent the interaction between PD-1 and its ligand, 
PDL-1, thus facilitating a positive immune response to kill the tumour. Several studies have indicated 
that antibodies that inhibit PD-1 and PDL-1 have prognostic capacities on many advanced malignancies 
and an efficient way to maintain the function of effector T cells. Inhibition of PD-1/PDL-1 interactions 
by specific antibodies may serve as an effective anti-tumour therapy. PD-1 pathway blockades will 
restore the activity of anti-tumour T cells that had become quiescent (Buchbinder and Desai, 2016).  
 
Monoclonal antibodies (mAbs) have been used as immune checkpoint inhibitors that inhibit the 
interaction of PD-1/PDL-1 pathway and overcome the conventional therapy for cancer treatment. 
mAbsare able to reduce solid tumours, suppress advanced tumours and metastasis, and diminish the 
toxicity within tolerable limits, contributing to the survival of cancer patients (Naidoo et al., 2015; 
Topalian et al., 2014). The checkpoint inhibitors are designed to either block PD-1 or PDL-1, hence 
turn on T-cell mediated immunity (Figure 1(B)).  
 
PD-1/PDL-1 immune checkpoint inhibitor against cervical cancer 
On December 2014, the Food and Drug Administration (FDA) had approved Nivolumab (Opdivo, 
Bristol-Myers Squibb), for treatment of patients suffers from metastatic or unrespectable melanoma 
(Alsaab et al., 2017). Nivolumab is PD-1 specific monoclonal antibody and it prevents the interaction 
of PDL-1 towards PD-1. In a clinical trial conducted by Hollebecque et al. (2017), treatment using 
Nivolumab demonstrated encouraging clinical outcomes among women with recurrent or metastatic 
cervical, vaginal and vulvar cancers. The study showed that progression-free survival rate (73.9%) was 
observed after three months, and overall survival (87.1%) was observed after six months. The overall 
response rate (ORR) across those three tumour types was 20.8% and the disease control rate (DCR) was 
70.8%. For future prospect, combination of immune checkpoint inhibitors is ongoing in clinical trials 
which involve co-targeting CTLA-4 and PD-1, in combination or sequential, in advanced-stage of 
melanoma patients. This synergism may be resulting in the amplification of T cells in lymphoid organs 
and tumour tissue by CTLA-4, while inhibition of PD-1 overcomes the immune suppression in tumour 
tissues (Ribas, 2012). This combination treatment is now being investigated in ovarian and cervical 
cancers (Ribas, 2012).  
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Oncolytic Virotherapy  
Oncolytic viruses selectively infect and kill cancerous cells/tissues without harming normal cells/tissues 
(Ferguson et al., 2012; Fukuhara et al., 2016; Russell et al., 2012). This character of oncolytic viruses 
has made them a potential modality in combating cancer which popularly known as oncolytic 
virotherapy nowadays. Oncolytic virotherapy is generally divided into two approaches using either 
naturally-occurring oncotropic viruses such as Newcastle disease virus, parvovirus, vesicular stomatitis 
virus and reovirus or using genetically modified viruses, which are engineered to attain selective 
oncolysis ability, such as adenovirus, herpes simplex virus and vaccinia virus (Motalleb, 2013). 
 
Viruses have attracted interest as potential anti-cancer therapeutic agents since early 19th century when 
tumour regressions have been documented following virus infection or vaccination, mostly seen in 
immunosuppressed patients (Liu et al., 2007). This is the foundation for clinical trials where body fluids 
containing animal or human viruses were used to transmit infections to cancer patients (Russell et al., 
2012). Among the earliest reports was the regression of cervical carcinoma after administration of rabies 
vaccine in 1912 (DePace, 1912). In 1956, a clinical trial using live adenoidal pharyngeal conjunctival 
against cervical cancer showed selective oncolytic effect of the virus limited to cancerous tissues (Smith 
et al., 1956). The practice was eventually abandoned due to uncontrolled toxicity (Fukuhara et al., 2016). 
However, with the invention of recombinant DNA technology, modification of viruses to improve their 
safety and anti-tumoural efficacy became possible (Kirn et al., 2001). 
 
Advantages and disadvantages of oncolytic virotherapy 
Oncolytic viruses destroy tumours by various mechanisms. A direct cell lysis can be achieved via the 
production of proteins that have direct cytotoxic effects on the tumour cells, through transgenes 
expression (Mullen and Tanabe, 2002). Elicitation of specific and non-specific immune response may 
enhance sensitivity of tumour cells to chemotherapy and radiotherapy (Goldufsky et al., 2013). 
 
Oncolytic virotherapy is generally safe (Ferguson et al., 2012; Goldufsky et al., 2013; Liu et al., 2007) 
as it lacks cross resistance with other therapeutic agents (Kirn et al., 2001; Motalleb, 2013). Oncolytic 
viruses allow for the insertion and expression of transgenes in tumour cells to achieve specific effect 
(Goldufsky et al., 2013), while offering synergistic activity with other therapeutic approaches 
(Prestwich et al., 2008). It is also possible to monitor virus spread in tumours through transgene 
expression monitoring (Russell et al., 2012). Moreover, the amplification of input dose is possible as 
virus replicates and release new virions (Sze et al., 2013). 
 
Nonetheless, oncolytic virotherapy does carry some drawbacks. The disadvantages include the presence 
of pre-existing immunity to the virus as a result of primary infection and/or previous immunization or 
oncolytic virotherapy, which limits the virus spread (Ferguson et al., 2012). In addition, virus 
neutralization by antibodies, inactivation by complements, non-specific uptake by other tissues such as 
the liver and spleen, and poor virus discharge from the vascular compartment following intravenous 
administration have been reported (reviewed by Wong et al., 2010). 
 
Enhancing viral delivery 
Various approaches to enhance viral delivery to tumour cells have been suggested. Viruses can be 
delivered intra-tumourally to avoid arrest by immune cells, although systemic delivery would be 
required for metastatic cancer therapy (Ferguson et al., 2012; Russell et al., 2012). The usage of non-
human animal viruses to prevent their rapid eradication by pre-existing antibodies has also been 
suggested (Kelly and Russel, 2007).  
 
Other suggestions are ultrasound delivery of viruses using microbubbles (Liang et al., 2010),  utilization 
of carrier cells to hide and deliver viruses to tumour beds (Russell et al., 2012) and polymer coating of 
viruses which can enhance their intravenous delivery to tumours (Fisher and Seymour, 2010). Immune 
suppression could also be used to increase intratumoural virus spread but this approach could diminish 
cross-priming of anti-cancer immunity (Russell et al., 2012). 
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Despite the clinical achievement of oncolytic virotherapy, efficacy has not been observed in all patients 
and cancer types (Plitt and Zamarin, 2015). Future researches should focus on optimal choice of viruses, 
tumour types and stages of disease, viral dosage, routes of delivery, and recognizing possible 
combinations that may boost their pharmacological mechanisms of action (Goldufsky et al., 2013). 
 
Oncolytic virotherapy against cervical cancer 
Development of an increasingly effective oncolytic virotherapy has also increases the possibility of 
toxicity to normal cells. Therefore, current researches are trying to control the virus replication in 
normal cells upon delivery and expression to occur strictly at the targeted cancer cells. The ability to 
selectively stimulates replication at tumour cells only and diminish the replication if toxicity is 
evidenced could provide better safety and efficacy of oncolytic virotherapy.  
 
In one study, Kanerva et al. (2008) uses adenoviruses containing the cyclooxygenase-2 (Cox-2) or 
vascular endothelial growth factor (VEGF) promoter to restrict viral replication to target tissues 
expressing the promoters, which are the tumour tissues. Expressions of Cox-2 and VEGF have been 
linked with tumour invasiveness and angiogenesis and undetected in the normal epithelial lining of the 
cervix (Cao and Prescott, 2002). Overexpression of Cox-2 and VEGF leads to chemotherapy resistance 
and poor survival rate of cervical cancer patients. Kanerva et al. (2008) also concluded that prior pre-
treatment with anti-inflammatory reagent dexamethasone, on cervical cancer cells in vitro, able to 
reduce the replication of oncolytic adenovirus carrying Cox-2 and VEG-F promoters in cancer cells. 
The usage of this steroid offers a safety switch for oncolytic virotherapy in case the tumour-specific 
promoters mediate any side effect in clinical trial.  
 
Other than adenoviruses, a novel oncolytic Sindbis virus has been shown to successfully induce the 
cytopathic effects and apoptosis of two cervical cancer cells HeLaS3 and C33A. Its in vivo study 
demonstrated a site-specific and significant cervical tumour regression in nude mice upon 
intraperitoneal and intravenous virus inoculations (Unno et al., 2005). 
 
It is suggested that combination of oncolytic virotherapy with other therapeutic agents may increase 
anti-cancer effects (Motalleb, 2013). Application of recombinant herpes simplex virus type I increases 
anti-tumour activity against cervical cancer when combined with radiation therapy (Blank et al., 2004). 
Valproic acid also improves oncolytic effect of rat parvovirus H-1PV synergistically against cervical 
cancer (Li et al., 2013). Combination of neoadjuvant chemotherapy with a recombinant human 
oncolytic adenovirus-p53 also offers better efficacy, safety and synergism in treating locally advanced 
cervical cancer patients of stage IB2 to IIIA (Xiao et al., 2017).  
 
Gene Therapy  
Gene therapy can be used to treat genetically inherited disease or cancer by transferring genetic 
materials into patients’ target cells to enhance or inhibit a specific protein expression (Podolska et al.,  
2012; Scholz and Wagner, 2012) without affecting the normal cells (Carrington, 2015). Gene therapy, 
also known as targeted therapy, may cause changes in the genetic materials of the patients (Kumar, 
2016) and can be classified into two main groups, the germ line gene therapy and the somatic gene 
therapy (Ibraheem et al., 2014).  
 
According to Ibraheem et al. (2014), germ line gene therapy involved alteration of the gene therapy in 
the germ cell of reproductive system, while somatic gene therapy occurs when genetic modification 
took place in the non-reproductive system cells. The germ line gene therapy is transmissible throughout 
several generations but the somatic gene therapy is restricted to only the patient who is treated with it 
(Ibraheem et al., 2014). Germ line gene therapy is transmissible due to the integration of the gene into 
the chromosome of the targeted genome location, whilst somatic gene therapy targeted the  non-
heritably genetic material, hence limits its transmission (Stribley et al., 2002). 
 
In cancer treatment, gene therapy is used to target the abnormal gene, to increase the susceptibility of 
the cell towards drugs or conventional therapy, to induce cell apoptosis, to block oncogene expression 
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and to enhance tumour cell immunogenicity recognition (Das et al., 2014). Gene therapy can be applied 
to a patient by either a direct transfer or by using living cell-based approach (Figure 2). 
 
Figure 2: Representative of process flow for the two types of gene delivery approach for gene 
therapy; direct and living cell-based delivery (reproduced from NIH Stem Cell Information (2016)). 
 
In direct transfer, the gene of interest will be packed in liposomes or any other biological microparticles. 
These microparticles are then injected directly to the patients which resulted in gene or protein 
expression at the targeted organ.  Gene therapy using living cells involves isolation and propagation of 
patient’s cells, introduction of therapeutic gene into the cell and re-introduction of the transformed cells 
to the patient (NIH Stem Cell Information, 2016).  
 
For a successful delivery of the genetic modification component, “vehicles” are designed to create a 
secure and efficient genetic material carrier towards the target (Ibraheem et al., 2014). These carriers 
are important to carry genetic materials in a stable manner, and at the same time must cross the cell 
membrane and deliver the gene of interest to the targeted organ. There are many considerations for the 
development of a carrier, such as delivery method to the target, uptake mechanism by the targeted cell, 
arrival and recognition at the target (El-Aneed, 2004; Ibraheem et al., 2014; Narayan and Murty, 2010). 
There are now a wide variety of carriers that are used for gene therapy.  
 
Types of carrier used in gene therapy  
Traditionally, methods for gene therapy against cancer includes viral vectors, non-viral vectors (naked 
DNA), plasmids, bacteria vectors, liposomes, polymers, and molecular conjugates (Liu et al., 2014; Teo 
et al., 2016). More recently, carriers are developed based on proteins, such as the polyethylene glycol-
polylactic acid (PEG-PLA) block copolymer (Liu et al., 2014).  
 
Viral vectors are constructed by manipulating the viral genome through removing and/or replacing the 
virulence gene before adding with the gene of interest. Viral vectors are efficient as they can infect and 
replicate inside a host cell by releasing their genome into the host’s intracellular environment (Shen and 
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Post, 2007). Meanwhile, for non-viral vectors which consist of combination of naked DNA with 
nanoparticles or chemicals and delivered into cells via physical or chemical aid offers few advantages. 
These advantages include ease of preparation and scale up and ability to accommodate various size of 
therapeutic DNA. In addition, the non-viral vectors do not exert any type of immune responses in 
targeted cells thus can be inoculated into patient repeatedly (Schmidt-Wolf and Schmidt-Wolf, 2003). 
The development of non-viral vectors and protein carriers is intended to reduce the toxicity effects on 
host cells upon administration (He et al., 2010).  
 
Gene therapy against cervical cancer 
Recently, a group of researchers was able to inactivate two oncogenes of high-risk HPV-18, using 
Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (CRISPR/Cas) technology. Kennedy 
et al., (2014) designed a single guide RNAs (sgRNAs) specific for E6 or E7 gene deletion and insertion 
mutations. The Cas9/sgRNA was delivered to the cells via transfection or lentiviral transduction. The 
resulting cleavage of HPV genome induces host cell tumour suppressor p53 and retinoblastoma (Rb) 
proteins to perform their functions, leading to cell cycle arrest, senescence, and apoptosis of the infected 
cells. 
 
In another study, a high gene transfer efficiency was observed using an adeno-associated virus (AAV) 
vector encoding short hairpin RNA (shRNA) against the E6 and E7 of HPV-16 in three different 
cervical cancer cell lines (BOKU, SiHa and SKG-IIIa cells) (Sato et al., 2018). shRNA is known to 
constantly inhibiting target gene expression for longer periods of time. Sato et al. (2018) demonstrated 
that the AAV-shRNA was able to reduce the mean volume of 8-mm major axis cervical tumours in 
mice. Furthermore, the expression levels of E6 and E7 was decreased, whereas the expression levels of 
tumour suppressors p53, p21 and pRb proteins were increased upon treatment, compared to the control, 
without exhibiting any adverse effects to the host. 
 
Conclusion 
With the advancement of science and technologies, higher chances of cancer recovery are possible. 
Although some of the treatments are still in the phase of clinical trials, promising results are evidenced, 
thus, approval of such treatments are imminent. Exploring the causes of the diseases and ways to modify 
our genome or tweaks our immunity enable researchers to develop more targeted treatments to cure all 
types of cancer, hence minimise cancer-related deaths in future.  
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